Gufic Biosciences Limited

Gufic Biosciences reported Q4 FY26 revenue of INR252 crores, a 15% YoY increase, with PAT more than doubling to INR20.5 crores. The Indore CMO facility reached 30% capacity utilization and EBITDA brea

Gufic Biosciences issues corrigendum clarifying its May 29, 2026 disclosure regarding share subscription in Saraswat Co-operative Bank. Clarifies subscription is a mandatory share-linkage requirement

Gufic Biosciences issues corrigendum to clarify its ₹230 crore borrowing-linked share subscription in Saraswat Co-operative Bank. Subscription is mandatory requirement under RBI norms for borrower mem

Gufic Biosciences reported 15% YoY revenue growth to ₹94,047.54 lakhs for FY26, though net profit declined 10% to ₹6,314.87 lakhs. The Board recommended a final dividend of ₹0.10 per equity share (10%